CliffBio
biologic

Aldurazyme

laronidase

Loss of exclusivityApril 2015projected — 12-year biologic exclusivity estimate
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameAldurazyme
Active ingredientlaronidase
Strength2.9MG/5ML (0.58MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2003
Marketing statusRx

More from Biomarin Pharmaceutical

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Aldurazyme patent cliff — loss of exclusivity April 2015 | CliffBio